GLP-1 Prescribing Shifts From Type 2 Diabetes to Obesity

Medscape July 23, 2024
Miriam Tucker

TOPLINE:

Since 2020, prescribing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for obesity without diabetes has risen, whereas their use for the treatment of type 2 diabetes (T2D) has declined.

METHODOLOGY:

• This population-based study used TriNetX, a real-time federated health research network with de-identified records of about 45 million people with at least one outpatient or inpatient visit in the United States during 2011-2023.

TAKEAWAY:

• There were a total of 871,854 new GLP-1 RA users during the study period.
• There was a decreasing trend in the proportion of new GLP-1 RA users with T2D, with a simultaneous twofold increase in the proportion of users without T2D but with a body mass index (BMI) of ≥ 30...

Today's Sponsors

Today's Sponsor